logo-loader
viewArecor

Arecor extends collaboration with top five pharmaceutical firm for new medicine formula

Under the deal, the pharma firm will fund a feasibility study into a liquid formulation of a ready-to-administer medicine using Arecor's Arestat technology

Arecor - Arecor extends collaboration with top five pharmaceutical firm for new medicine formula

Arecor Ltd has inked a further collaboration agreement with a top five pharmaceutical company to develop a liquid formulation of a ready-to-administer (RTA) medicine using its Arestat technology.

The biopharma group said its partner will fund a feasibility study into the formula and will retain an exclusive option to a global royalty bearing licence for the product and Arecor’s associated IP.

READ: Arecor signs agreement with Hikma Pharma to develop new injectable medicine

"This is the second RTA collaboration that we have announced in recent weeks involving our proprietary technology platform Arestat. It is a further project for an existing pharmaceutical partner which demonstrates the value of our technology and expertise together with the strength of our commercial relationships”, said Arecor chief executive Sarah Howell.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arecor's Sarah Howell discusses results from successful phase I insulin trial

Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Andrew Scott following the successful completion of the phase I trial for its ultra-rapid acting insulin for diabetics. She says the product was shown to have a favourable profile when compared with standard treatments and the...

on 17/12/19

2 min read